Results 121 to 130 of about 3,424,855 (336)
The Paradox in Translational Medicine
Clinical Chemistry, 2007 Advances in laboratory sciences have raised expectations of discovery of clinically useful biomarkers, but few such new tests have appeared to date. Hortin et al. (1) highlighted several challenges in the translation of promising markers into clinical laboratory tests.
LIPPI, Giuseppe +2 more
openaire +1 more source
Molecular Oncology, EarlyView.Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard +12 more
wiley +1 more source
Beyond the bedside: Re-imagining narrative medicine for knowledge translation
Encounters in TranslationThis article challenges the conventional dichotomy between narrative medicine and translational medicine, arguing that they are not opposites but mutually interdependent frameworks within medical research and practice.
Eivind Engebretsen
doaj +1 more source
Effective knowledge management in translational medicine
Journal of Translational Medicine, 2010 Background The growing consensus that most valuable data source for biomedical discoveries is derived from human samples is clearly reflected in the growing number of translational medicine and translational sciences departments across pharma as well as ...
Khasanova Tatiana +3 more
doaj +1 more source
N-myristoylation: from cell biology to translational medicine
Acta Pharmacologica Sinica, 2020 Various lipids and lipid metabolites are bound to and modify the proteins in eukaryotic cells, which are known as ‘protein lipidation’. There are four major types of the protein lipidation, i.e.
Meng Yuan +6 more
semanticscholar +1 more source
Molecular Oncology, EarlyView.ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang +8 more
wiley +1 more source
Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA
Molecular Oncology, EarlyView.Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson +2 more
wiley +1 more source
Capturing Scientific Knowledge on Medical Risk Factors [PDF]
, 2015 In this paper, we describe a model for representing scientific knowledge of risk factors in medicine in an explicit format which enables its use for automated reasoning. The resulting model supports linking the conclusions of up-to-date clinical research
Domingue, John +5 more
core
RETRACTION: eNOS Gene Polymorphisms in Perinatal Hypoxic-Ischemic Encephalopathy [PDF]
Journal of Pathology and Translational Medicine, 2019 Journal of Pathology and Translational Medicine Editors
doaj +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
Molecular Oncology, EarlyView.CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source